Neurometabolic therapy of mild cognitive impairment in patients with chronic cerebral ischemia

Close metadata

OBJECTIVE

To evaluate the effect of a sequential therapy regimen with Mexidol (500 mg injections intravenously for 14 days) and Mexidol FORTE 250 (250 mg tablets 3 times a day for 60 days) on higher cortical functions in patients with moderate cognitive disorders in chronic cerebral ischemia.

MATERIAL AND METHODS

A comparative, prospective study included 63 patients with chronic cerebral ischemia with moderate cognitive impairment. All patients received basic therapy aimed at reducing risk factors (antihypertensive, antithrombotic drugs as indicated). Patients of the main group (30 people: 12 men, 18 women) received Mexidol intravenously 500 mg in 100 ml of 0.9% NaCl solution once a day for 14 days, then Mexidol FORTE 250 (film-coated tablets) 250 mg 3 times a day for the next 60 days. The comparison group consisted of 33 patients (14 men, 19 women) who received only basic therapy. The groups were comparable in terms of age, sex characteristics and severity of cognitive deficit. We examined cognitive status (MoCA scale, Frontal Dysfunction Battery, 10 Word Memorization tests), severity of asthenia (MFI-20 scale), anxiety and depression (HADS scale), patient’s subjective assessment of the dynamics of the condition (CGI-improvement scale) in 1st, 14th and 74th±5 days of observation. On days 1 and 74±5 of observation, patients were examined using transcranial magnetic stimulation to study the neuronal activity of the cerebral cortex.

RESULTS

In the main group, at the time of completion of taking Mexidol and Mexidol FORTE 250, a pronounced cognitive regression was noted (MoCA scale +3 points, difference with the comparison group 1 point (p<0.0001); Frontal Dysfunction Battery test +4 points, difference with comparison group 2 points (p<0.001); memory test «10 words» +2 points, difference with the comparison group 1 point (p<0.05), emotional (HADS anxiety scale –8 points, difference with the comparison group 3 points (p<0.001), depression –3.5 points, difference with the comparison group 1.5 points (p<0.01), asthenic disorders (MFI-20 scale –30 points, difference with the comparison group 15.5 points (p<0.01), improvement in the well-being of patients (CGI-improvement scale –2 points, difference with the comparison group 1 point (p<0.0001). According to the transcranial magnetic stimulation performed, a statistically significant decrease in the central motor conduction time at the level of 1 and 2 motor neurons of the pyramidal tract bilaterally from the start to the end of therapy with Mexidol and Mexidol FORTE 250 was determined (p<0.01). An inverse correlation was found between the time of central motor conduction and the results of the Frontal Dysfunction Battery test at the same time points with left-sided localization of 1 motor neuron (p<0.01). The results of a study of the use of sequential therapy with Mexidol 500 mg IV drip 1 time per day for 14 days followed by oral administration of Mexidol FORTE 250 1 tablet 3 times a day for 60 days indicate its clinical effectiveness and safety in patients with chronic cerebral ischemia with mild cognitive impairment, and also confirm its importance for preventing the progression of cognitive disorders.

Keywords:

chronic cerebral ischemia

mild cognitive impairment

Mexidol

MoCA scale

frontal dysfunction

transcranial magnetic stimulation

Authors:

Antipenko E.A.

Privolzhsky Research Medical University

SPIN RSCI: 7708-9068
Scopus AuthorID: 34871353400
ORCID: 0000-0002-8972-9150

Shulyndin A.V.

Vectorpharm

ORCID: 0000-0003-2822-9934

Belyakov K.M.

Nizhny Novgorod Regional Clinical Hospital named after. N.A. Semashko

ORCID: 0000-0002-4768-1355

Received:

31.01.2024

Accepted:

02.02.2024

List of references:

Bogolepova AN. Features of pharmacotherapy of vascular cognitive impairment in the elderly. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2023;123(9):15-20. (In Russ.). https://doi.org/10.17116/jnevro202312309115
Stroke: modern technologies of diagnosis and treatment. Manual for physicians. Ed. by Piradov M.A., Tanashyan M.M., Maksimova M.Yu. 3 rev. M.: Medpress-inform; 2018. (In Russ.).
Chukanova EI, Chukanova AS. Efficacy and safety of the drug mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2019;119(9):39-45. (In Russ.). https://doi.org/10.17116/jnevro201911909139
Bogolepova AN, Vasenina EE, Gomzyakova NA, et al. Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(10-3):6-137. (In Russ.). https://doi.org/10.17116/jnevro20211211036
Katunina EA. Cognitive functions. What do we know about them? Directions of prevention and treatment. M.: AST 345 LLC; 2020. (In Russ.).
Tanashyan MM, Lagoda OV, Antonova KV, Raskurazhev AA. The main pathogenetic mechanisms of development of vascular pathology of the brain in atherosclerosis and metabolic syndrome: search for ways of correction. Annals of Clinical and Experimental Neurology. 2016;2(1):23-28. (In Russ.).
Ostroumova TM, Ostroumova OD. The importance of identifying and diagnosing signs of damage to signs of brain damage. Non Nocere. New Therapeutic Journal. 2020;(11):4-5. (In Russ.).
Zaharov VV, Tkacheva ON, Mkhitaryan EA, Fedin AI. Efficacy of Mexidol in patients with chronic brain ischemia and cognitive impairment of different age groups (results of sub-analysis of the international multicenter, randomized, double-blind, placebo-controlled study of sequential therapy in patients with chronic brain ischemia MEMO). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2022;122(11-2):73-80. (In Russ.). https://doi.org/10.17116/jnevro202212211273
Suponeva NA, Bakulin IS, Poidasheva AG, Piradov MA. Safety of transcranial magnetic stimulation: a review of international recommendations and new data. Neuromuscular Diseases. 2017;7(2):21-36. (In Russ.). https://doi.org/10.17650/2222-8721-2017-7-2-21-36
Litvinenko IV, Odinak MM, Emelin AYu, et al. The role of transcranial magnetic stimulation in the diagnosis of pathophysiological mechanisms of cognitive impairment in traumatic brain injury. Bulletin of the Russian Military Medical Academy. 2015;3(51):249-254. (In Russ.).
Khit MA, Nikitin SS, Gushcha AO. The role of transcranial magnetic stimulation in the diagnosis of cervical spondylogenic myelopathy. Annals of Clinical and Experimental Neurology. 2012;2:23-28. (In Russ.).
Sachdev P, Kalaria R, O’Brien J, et al. Internationlal Society for Vascular Behavioral and Cognitive Disorders. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-218. https://doi.org/10.1097/WAD.0000000000000034
Fedin AI, Zaharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(11):7-16. (In Russ.). https://doi.org/10.17116/jnevro20211211117
Voronina TA, Ivanova EA. Combined administration of mexidol with known medicines. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(4):115-124. (In Russ.). https://doi.org/10.17116/jnevro2019119041115
Stakhovskaya LV, Shamalov NA, Khasanova DR, et al. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(3-2):55-65. (In Russ.). https://doi.org/10.17116/jnevro20171173255-65
Stakhovskaya L, Shamalov N, Khasanova N, et al. Results of a Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Effi cacy and Safety of Mexidol in Prolonged Sequential Therapy of Patients in the Acute and Early Recovery Stages of Hemispheric Stroke (the EPICA study). Neurosci Behav Physiol. 2018;48(8):929-938. https://doi.org/10.1007/s11055-018-0652-y
Shchepankevich LA, Nikolaev YuA, Dolgova NA, Chipova DT. Optimization of hypolipidemic therapy in patients with ischemic stroke and diabetes mellitus. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(2):42-45. (In Russ.). https://doi.org/10.17116/jnevro20161162142-45
Solov’eva ÉIu, Karneev AN, Tyutyumova EA. Correction of pathological conditions associated with insulin-resistant hyperglycaemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(9):116-125. (In Russ.). https://doi.org/10.17116/jnevro201611691116-125
Zakharov VV, Ostroumova OD, Kochetkov AI, et al. An international multicenter randomized, double-blind, placebo-controlled study assessing the effectiveness and safety of sequential therapy of patients with chronic cerebral ischemia with Mexidol and Mexidol FORTE 250 (MEMO study): results of a subanalysis in patients with arterial hypertension. Therapy. 2023;9(1):145-159. (In Russ.).
Vizilo TL, Arefieva EG. Improving the effectiveness of pharmacotherapy in comorbid patients with chronic cerebral ischemia on an outpatient basis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2023;123(3):51-55. (In Russ.). https://doi.org/10.17116/jnevro202312303151
Gribacheva IA, Popova TF, Petrova EV, Zvonkova AV. Possibilities of multimodal neuroprotection in patients with chronic cerebral ischemia on the background of arterial hypertension and atherosclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(2):19-26. (In Russ.). https://doi.org/10.14412/2074-2711-2023-2-19-26
Zhuravleva MV, Arhipov VV, Vasyukova NS, et al. Results of clinical studies of the efficacy and safety of the use of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2022;122(11):29-39. (In Russ.). https://doi.org/10.17116/jnevro201911912146

Close metadata